Plato Investment Management Ltd Invests $1.31 Million in Boston Scientific Corporation $BSX

Plato Investment Management Ltd bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 30,788 shares of the medical equipment provider’s stock, valued at approximately $1,306,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BSX. Kelleher Financial Advisors purchased a new stake in shares of Boston Scientific in the second quarter worth $25,000. FWL Investment Management LLC purchased a new position in Boston Scientific in the second quarter worth about $26,000. Swiss RE Ltd. purchased a new position in Boston Scientific in the fourth quarter worth about $26,000. Garton & Associates Financial Advisors LLC bought a new position in shares of Boston Scientific in the fourth quarter worth approximately $26,000. Finally, Clal Insurance Enterprises Holdings Ltd purchased a new stake in shares of Boston Scientific during the first quarter valued at approximately $28,000. Institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on BSX shares. TD Cowen reduced their price target on shares of Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Mizuho cut their target price on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Truist Financial reduced their target price on Boston Scientific from $62.00 to $57.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Oppenheimer decreased their price target on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a research note on Monday, July 27th. Finally, Bank of America dropped their price objective on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director David C. Habiger acquired 2,250 shares of the stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the purchase, the director directly owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Edward J. Ludwig acquired 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The stock was acquired at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. The trade was a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders acquired 202,122 shares of company stock valued at $9,813,931. Company insiders own 0.34% of the company’s stock.

Boston Scientific Trading Down 0.7%

NYSE:BSX opened at $51.46 on Tuesday. The company has a market cap of $74.58 billion, a PE ratio of 20.83, a price-to-earnings-growth ratio of 1.13 and a beta of 0.56. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The company has a 50 day simple moving average of $46.12 and a two-hundred day simple moving average of $58.81. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the prior year, the firm earned $0.75 EPS. The company’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has authorized a stock buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.